| Literature DB >> 35683474 |
Rianne N M Hogenbirk1, Louise B D Banning2, Anita Visser3,4, Harriet Jager-Wittenaar3,5, Robert A Pol2, Clark J Zeebregts2, Joost M Klaase1.
Abstract
Low muscle mass is associated with adverse outcomes after surgery. This study examined whether facial muscles, such as the masseter muscle, could be used as a proxy for generalized low muscle mass and could be associated with deviant outcomes after carotid endarterectomy (CEA). As a part of the Vascular Ageing study, patients with an available preoperative CT-scan, who underwent an elective CEA between December 2009 and May 2018, were included. Bilateral masseter muscle area and thickness were measured on preoperative CT scans. A masseter muscle area or thickness of one standard deviation below the sex-based mean was considered low masseter muscle area (LMA) or low masseter muscle thickness (LMT). Of the 123 included patients (73.3% men; mean age 68 (9.7) years), 22 (17.9%) patients had LMA, and 18 (14.6%) patients had LMT. A total of 41 (33.3%) patients had a complicated postoperative course and median length of hospital stay was four (4-5) days. Recurrent stroke within 5 years occurred in eight (6.6%) patients. Univariable analysis showed an association between LMA, complications and prolonged hospital stay. LMT was associated with a prolonged hospital stay (OR 8.78 [1.15-66.85]; p = 0.036) and recurrent stroke within 5 years (HR 12.40 [1.83-84.09]; p = 0.010) in multivariable logistic regression analysis. Masseter muscle might be useful in preoperative risk assessment for adverse short- and long-term postoperative outcomes.Entities:
Keywords: carotid endarterectomy; computed tomography; frailty; masseter muscle; risk management; sarcopenia
Year: 2022 PMID: 35683474 PMCID: PMC9181694 DOI: 10.3390/jcm11113087
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Figure 1Example of performed measurements of bilateral masseter muscle area (left) and thickness (middle) after tilt adjustments were performed (right).
Comparison of clinical characteristics by presence of adequate or low masseter muscle area and adequate or low masseter muscle thickness.
| Demographics | Masseter Muscle Area | Masseter Muscle Thickness | |||||
|---|---|---|---|---|---|---|---|
| All Patients | AMA | LMA | AMT | LMT | |||
| Sex | |||||||
| Male | 90 (73.2%) | 74 (73.3%) | 16 (72.7%) | 0.959 | 76 (72.4%) | 14 (77.8%) | 0.633 |
| Female | 33 (26.8%) | 27 (26.7%) | 6 (27.3%) | 0.959 | 29 (27.6%) | 4 (22.2%) | 0.633 |
| Age—y | 68 (9.7) | 68 (9.9) | 71 (8.7) | 0.652 | 68 (10.3) | 69 (6.1) | 0.475 |
| BMI—kg/m2 | 27.2 (4.5) | 27.6 (4.5) | 25.1 (3.1) | 0.014 | 27.6 (4.6) | 24.9 (3.1) | 0.021 |
| Smoking status | |||||||
| Current | 33 (26.8%) | 24 (23.8%) | 9 (40.9%) | 0.087 | 23 (21.9%) | 10 (55.6%) | 0.005 |
| History | 38 (30.9%) | 35 (34.7%) | 3 (13.6%) | 0.041 | 34 (32.4%) | 4 (22.2%) | 0.389 |
| Never | 52 (42.3%) | 42 (41.6%) | 10 (45.5%) | 0.814 | 48 (45.7%) | 4 (22.2%) | 0.051 |
| ASA ≥ 3 | 60 (48.7%) | 45 (44.6%) | 15 (68.1%) | 0.037 | 45 (42.9%) | 15 (83.3%) | 0.001 |
| Charlson Comorbidity Index—median (IQR) | 5 (3–6) | 5 (3–6) | 5 (4–5) | 0.806 | 4 (3–6) | 5 (4–5) | 0.496 |
| Partial or full dental prosthesis | 65 (52.8%) | 54 (53.5%) | 11 (50.0%) | 0.446 | 53 (50.5%) | 12 (66.7%) | 0.234 |
| GFI | 2 (1–4) | 2 (1–4) | 2 (1–5) | 0.827 | 2 (1–4) | 2 (1–5.25) | 0.233 |
| GFI > 3 | 34 (27.6%) | 28 (27.7%) | 6 (27.3%) | 0.966 | 28 (26.7%) | 6 (33.3%) | 0.559 |
| Indication | |||||||
| Asymptomatic | 19 (15.4%) | 16 (15.8%) | 3 (13.6%) | 0.795 | 18 (17.1%) | 1 (5.6%) | 0.209 |
| Amaurosis | 17 (13.8%) | 16 (15.8%) | 1 (4.5%) | 0.164 | 15 (14.3%) | 2 (11.1%) | 0.718 |
| Transient ischemic attack | 41 (33.3%) | 33 (32.7%) | 8 (36.4%) | 0.739 | 37 (35.2%) | 4 (22.2%) | 0.279 |
| Minor ischemic stroke | 46 (37.4%) | 36 (35.6%) | 10 (45.5%) | 0.389 | 35 (33.3%) | 11 (61.1%) | 0.024 |
| Ipsilateral stenosis (%) | |||||||
| <50% | 2 (1.6%) | 1 (1.0%) | 1 (4.5%) | 0.232 | 1 (1%) | 1 (5.6%) | 0.154 |
| 50–70% | 22 (17.9%) | 17 (16.8%) | 5 (22.7%) | 0.513 | 22 (21%) | 0 (0%) | 0.032 |
| >70% | 99 (80.5%) | 83 (82.2%) | 16 (72.7%) | 0.311 | 82 (78%) | 17 (94.4%) | 0.106 |
Low muscle area and thickness were defined by a mean masseter muscle area or thickness of one standard deviation below the sex-based mean. Data are presented as mean (SD) or median (IQR), unless indicated otherwise. AMA: adequate masseter muscle area; LMA: low masseter muscle area; AMT: adequate masseter muscle thickness; LMT: low masseter muscle thickness; BMI: body mass index; ASA: American Society of Anesthesiologists’ score; GFI: Groningen Frailty Indicator.
Comparison of clinical outcomes by presence of adequate or low masseter muscle area and adequate or low masseter muscle thickness.
| Clinical Outcomes | Masseter Muscle Area | Masseter Muscle Thickness | |||||
|---|---|---|---|---|---|---|---|
| All Patients | AMA | LMA | AMT | LMT | |||
| Complications within 30 days | 41 (33.3%) | 30 (29.7) | 11 (50.0%) | 0.067 | 34 (32.4%) | 7 (38.9%) | 0.588 |
| Cardiac complication | 6 (4.9%) | 4 (4.1%) | 2 (9.1%) | 0.311 | 1 (5.0%) | 1 (5.6%) | 0.885 |
| Hyper/hypotension | 9 (7.3%) | 5 (5.0%) | 4 (18.2%) | 0.031 | 6 (5.7%) | 3 (16.7%) | 0.099 |
| Stroke | 6 (4.9%) | 4 (4.0%) | 2 (9.1%) | 0.311 | 4 (3.8%) | 2 (11.1%) | 0.184 |
| Wound | 8 (6.5%) | 7 (6.9%) | 1 (4.5%) | 0.681 | 7 (6.7%) | 1 (5.6%) | 0.860 |
| Nerve injury | 15 (12.2%) | 13 (12.9%) | 2 (9.1%) | 0.623 | 15 (14.3%) | 0 (0%) | 0.087 |
| Other | 3 (2.4%) | 2 (2.0%) | 1 (4.5%) | 0.480 | 3 (2.9%) | 0 (0%) | 0.468 |
| Complications in CCI, median (IQR) | 0 (0–8.7) | 0 (0–8.7) | 0 (0–20.9) | 0.082 | 0 (0–8.7) | 0 (0–20.9) | 0.624 |
| Length of hospital stay (days), median (IQR) | 4 (4–5) | 4.50 (4–5) | 5.5 (4–7) | 0.011 | 4 (4–5) | 4 (4–7.25) | 0.621 |
| Hospital stay ≥ 7 days | 15 (12.2%) | 9 (8.9%) | 6 (27.3%) | 0.017 | 10 (9.5%) | 5 (27.8%) | 0.029 |
| Readmission within 30 days | 6 (4.9%) | 5 (5.0%) | 1 (4.5%) | 0.708 | 5 (4.8%) | 1 (5.6%) | 0.62 |
| Recurrent stroke within 5 years (beyond 30 days) | 8 (6.6%) | 6 (5.9%) | 2 (9.1%) | 0.587 | 5 (4.8%) | 3 (16.7%) | 0.058 |
| Transient ischemic attack | 4 (3.3%) | 3 (3.0%) | 1 (4.5%) | 0.706 | 3 (2.9%) | 1 (5.6%) | 0.551 |
| Ischemic stroke | 4 (3.3%) | 3 (3.0%) | 1 (4.5%) | 0.706 | 2 (1.9%) | 2 (11.1%) | 0.042 |
| 5-year survival | 102 (83.9%) | 85 (84.2%) | 17 (77.2%) | 0.531 | 88 (83.8%) | 14 (77.8%) | 0.368 |
Low muscle area and thickness were defined by a mean masseter muscle area or thickness of one standard deviation below the sex-based mean. Data are presented as mean (SD) or median (IQR), unless indicated otherwise. AMA: adequate masseter muscle area; LMA: low masseter muscle area; AMT: adequate masseter muscle thickness; LMT: low masseter muscle thickness; CCI: Comprehensive Complication Index
Univariable and multivariable linear and logistic regression analysis of the association between low masseter muscle area, low masseter muscle thickness, and surgical outcome.
| Low Masseter Muscle Area | Low Masseter Muscle Thickness | |||||||
|---|---|---|---|---|---|---|---|---|
| Outcome Parameter | Effect Size | 95%-CI | Effect Size | 95%-CI | ||||
| Lower | Upper | Lower | Upper | |||||
| Complications (CCI) | ||||||||
| Univariable analysis | 5.23 | 0.31 | 10.14 | 0.037 | 2.92 | −2.48 | 8.32 | 0.287 |
| Multivariable analysis * | 4.26 | −1.26 | 9.79 | 0.129 | 1.15 | −4.99 | 7.29 | 0.712 |
| Hospital stay ≥7 days | ||||||||
| Univariable analysis | OR 3.80 | 1.20 | 12.24 | 0.023 | OR 3.65 | 1.08 | 12.38 | 0.037 |
| Multivariable analysis ** | OR 4.73 | 1.13 | 19.73 | 0.033 | OR 8.78 | 1.15 | 66.85 | 0.036 |
| 5-year recurrent stroke risk (beyond 30 days) | ||||||||
| Univariable analysis | HR 1.70 | 0.34 | 8.4 | 0.518 | HR 4.04 | 0.96 | 16.93 | 0.056 |
| Multivariable analysis * | HR 2.05 | 0.29 | 14.62 | 0.473 | HR 12.40 | 1.83 | 84.09 | 0.010 |
| 5-year survival | ||||||||
| Univariable analysis | HR 1.56 | 0.58 | 4.31 | 0.374 | HR 1.54 | 0.52 | 4.59 | 0.436 |
| Multivariable analysis ** | HR 1.25 | 0.38 | 4.14 | 0.714 | HR 1.63 | 0.47 | 5.72 | 0.443 |
Low masseter muscle area and thickness were defined by a mean masseter muscle area of 1 standard deviation below the sex-based mean. * adjusted for: Sex; age; BMI; ASA score ≥ 3; dental status; current smoking. ** adjusted for: Sex; age; BMI; ASA score ≥ 3; dental status; current smoking; complications in CCI. CCI: Comprehensive Complication Index.
An overview of existing literature regarding CT-based masseter measurements and surgical outcome.
| Author (Year) | Population | Sample | Masseter Measurements | Results | ||
|---|---|---|---|---|---|---|
| Type of Measurements | Mean | Outcome Parameters | Effect Size [95%-CI] | |||
| Lindström et al. (2021) | Pre-operative before mechanical thrombectomy in acute ischemic stroke patients | 312 | Masseter area | M 450 mm2 | 3-month survival | OR 0.57 [0.35–0.91] |
| Masseter density | M 65.5 HUF 61 HU | 3-month survival | OR 0.61 [0.41–0.92] | |||
| Waduud et al. (2020) | Pre-operative before carotid endarterectomy | 149 | Masseter area | - | 30-day survival | HR 0.14 [0–5.44] |
| 1-year survival | HR 0.51 [0.13–2.07] | |||||
| 4-year survival | HR 0.36 [0.13–1.04] | |||||
| Overall survival | HR 0.38 [0.15–0.97] | |||||
| Masseter density | - | 30-day survival | HR 1.03 [0.95–1.10] | |||
| 1-year survival | HR 0.98 [0.95–1.01] | |||||
| 4-year survival | HR 0.98 [0.96–1.01] | |||||
| Overall survival | HR 0.97 [0.95–1.00] | |||||
| Masseter area × masseter density | - | 30-day survival | HR 0.99 [0.97–1.02] | |||
| 1-year survival | HR 0.99 [0.98–1.00] | |||||
| 4-year survival | HR 0.99 [0.98–1.00] | |||||
| Overall survival | HR 0.99 [0.99–1.00] | |||||
| Tanabe et al. (2019) | Geriatric trauma patients (≥65 years) admitted to the traumatic ICU | 327 | Masseter area | M 439 mm2 | 1-year mortality | HR 2 [1.20–3.10] |
| Oksala et al. (2019) | Pre-operative before carotid endarterectomy | 242 | Masseter area | M 420 mm2 | Long-term survival—Median follow-up 68 months | HR 0.75 [0.58–0.97] |
| Masseter density | M 55 HU | Long-term survival—Median follow up 68 months | HR 0.92 [0.76–1.12] | |||
| Hu et al. (2018) | Geriatric trauma patients (≥55 years) with sTBI | 108 | Masseter area | M 455 mm2 | 30-day mortality | HR 0.78 [0.62–0.97] |
| Masseter area 1SD below sex-based mean | - | Discharge disposition to home | 0% vs. 13%, | |||
| 30-day mortality | OR 2.95 [1.03–8.49] | |||||
| Wallace et al. (2016) | Blunt-injured trauma geriatric patients (≥65 years) | 357 | Masseter area | M 418 mm2 | 2-year mortality | HR 0.76 [0.60–0.96] |
Six studies have reported the association between CT-measured Masseter area or density and outcome after trauma or surgery. Data regarding mean masseter measurements were listed where available, and main conclusions of the studies are reported. M: male; F: female; sTBI: severe traumatic brain injury; HU = Hounsfield units; ICU: Intensive Care Unit.